Bispecific monoclonal antibody T-cell engager targeting BCMA on myeloma plasma cells and CD3 on T cells, redirecting T-cell cytotoxicity; administered subcutaneously.
Humanized bispecific monoclonal antibody that binds BCMA on malignant plasma cells and CD3 on T cells, crosslinking them to activate T-cell cytotoxicity and induce perforin/granzyme-mediated killing of BCMA-expressing myeloma cells.
Teclistamab bridges CD3 on T cells to BCMA on target cells, activating T cells to kill BCMA-expressing cells via perforin/granzyme-mediated cytotoxicity.
Anti-CD38 monoclonal antibody mediating ADCC, CDC, and ADCP and depleting immunosuppressive CD38+ cells; administered subcutaneously.
Anti-CD38 monoclonal antibody that binds CD38 on myeloma and immunosuppressive cells and induces cell killing via Fc-mediated ADCC, CDC, and ADCP, depleting CD38+ cells and enhancing antitumor immunity (administered subcutaneously).
Anti-CD38 antibody binds CD38 on target cells; its Fc recruits immune effectors and complement, causing ADCC, ADCP, and CDC to kill CD38+ cells.
An antibody–drug conjugate targeting HER2 that is internalized after binding, releasing the cytotoxic payload MMAE to disrupt microtubules and induce tumor cell apoptosis (with potential bystander effect).
Anti‑HER2 monoclonal antibody linked to MMAE. After binding HER2 on tumor cells, the ADC is internalized and releases MMAE, which disrupts microtubules (tubulin polymerization inhibition), causing cell-cycle arrest and apoptosis, with potential bystander killing of adjacent cells.
ADC binds HER2, is internalized, and releases MMAE, which inhibits tubulin polymerization, causing mitotic arrest and apoptosis (with possible bystander effect).
A HER2-targeted antibody-drug conjugate in which an anti-HER2 monoclonal antibody delivers an intracellular cytotoxic payload after HER2 binding and internalization; may also engage Fc-mediated effector functions.
An anti-HER2 IgG1 monoclonal antibody binds HER2 on tumor cells, is internalized, and releases a camptothecin-derived topoisomerase I inhibitor via a cleavable linker, stabilizing TOP1-DNA complexes, causing DNA strand breaks, blocking replication, and inducing apoptosis; the antibody may also mediate Fc-dependent effector functions (e.g., ADCC).
The anti-HER2 ADC binds HER2, is internalized, and releases a camptothecin-derived topoisomerase I inhibitor that causes DNA damage and apoptosis; the IgG1 may also induce Fc-mediated ADCC.
A TROP2-targeted antibody-drug conjugate comprising an anti-TROP2 monoclonal antibody linked to a cytotoxic payload that is delivered to TROP2-expressing tumor cells upon internalization.
Anti-TROP2 monoclonal antibody linked to a cytotoxic payload; binds TROP2 on tumor cells, is internalized, and releases the payload intracellularly to induce tumor cell death (e.g., via DNA damage or microtubule disruption), with potential Fc-mediated effector contributions.
The anti-TROP2 ADC binds TROP2, is internalized, and releases a cytotoxic payload that kills the cell (e.g., via DNA damage or microtubule disruption); Fc-mediated ADCC/CDC may also contribute.